The end of Novo Nordisk’s supply problems could bring new headaches for ... the Type 2 diabetes treatment Ozempic. However, ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Current health news briefs cover potential risks linked to Novo Nordisk's diabetes drug Ozempic, opposition to Robert F.

If coverage is structured properly, it could greatly help our country's chronic disease and obesity epidemics. But Donald Trump's Food and Drug Administration (FDA) will also need to ensure the drugs ...

Danish drugmaker Novo Nordisk (NVO) is investing $1.20 billion U.S. in a new facility that will produce medications to treat ...

On its own, obesity can cause acute ailments, including breathlessness and back pain. Worse, it often leads to other chronic ...

The U.S. Food and Drug Administration has declined to approve an injectable version of Johnson & Johnson's drug Rybrevant for ...

Americans pay more for health care but don't get better results. Why? The blame goes well beyond insurance companies.

Part of the joy of the season may be gone — or feel different — for people who are taking popular weight-loss drugs and can't ...

In a public health breakthrough, U.S. obesity rates have decreased for the first time in more than a decade, with new weight ...

Here are five things to know about GLP-1s and increased healthcare utilization: 1. According to the report, an uptick in GLP-1 use is facilitating a range of "crucial preventive care," including pap ...

The Danish Medicines Agency said it would ask European authorities to review two new studies that point to a link between ...